BACKGROUND Ascarid infections are among the most prevalent intestinal parasitic infections occurring in dogs around the world, with Toxocara canis and Toxascaris leonina commonly observed. Toxocara canis can cause considerable disease in dogs and humans, and year-round prophylactic treatment and control in dogs is recommended. Elimination of immature stages of these parasites before egg-laying will reduce environmental contamination and the risk of infection for both dogs and humans. Studies were conducted to evaluate the efficacy of a novel, oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced immature adult (L5) and adult T. canis, and adult T. leonina infections in dogs. METHODS Six negative-controlled, masked, randomized laboratory studies were conducted. Two studies each evaluated efficacy against immature adult (L5) T. canis, adult T. canis, and adult T. leonina. Sixteen to 40 dogs were included in each study. Dogs experimentally infected with the target parasite were dosed once on Day 0 with either placebo tablets or Simparica Trio™ tablets to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Efficacy was based on the number of worms recovered at necropsy 7-10 days after treatment compared to placebo control. RESULTS Based on geometric mean worm counts, efficacy of the sarolaner + moxidectin + pyrantel combination was ≥ 95.2% against immature adult T. canis, ≥ 97.3% against adult T. canis, and ≥ 89.7% against adult T. leonina. There were no treatment-related adverse events in any study. CONCLUSIONS These studies confirm the efficacy of a single dose of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against immature adult and adult T. canis, and adult T. leonina infections in dogs.

中文翻译：

---

含有sarolaner，moxidectin和pyrantel（Simparica Trio™）的新型口服咀嚼片对狗的a螨感染的功效。

背景技术scar虫感染是全世界狗中最普遍的肠道寄生虫感染之一，通常观察到犬Toxocara canis和Toxascaris leonina。犬弓形虫可在犬和人中引起相当大的疾病，因此建议对犬进行全年的预防性治疗和控制。在产卵前消除这些寄生虫的未成熟阶段将减少环境污染并减少狗和人的感染风险。进行研究以评估含有sarolaner，moxidectin和pyrantel（Simparica Trio™）的新型口服咀嚼片对狗的未成熟成年（L5）和成年犬T. leonina感染的功效。方法进行了六项阴性对照，掩盖的随机实验室研究。两项研究均评估了对未成年成年犬（L5）T. canis，成年犬T. canis和成年犬T. leonina的功效。每个研究中包括16至40只狗。实验上感染目标寄生虫的狗在第0天用安慰剂片剂或Simparica Trio™片剂给药一次，以提供最低剂量：1.2 mg / kg sarolaner，24 µg / kg moxidectin和5.0 mg / kg吡咯烷（作为pa酸盐）。功效基于与安慰剂对照相比在治疗后7-10天尸检时发现的蠕虫数量。结果根据几何平均蠕虫计数，sarolaner + moxidectin + pyrantel组合对未成年成年犬T. canis的疗效≥95.2％，对成年成犬T. canis≥97.3％，对成年T. leonina成虫≥8.9.7％。在任何研究中都没有治疗相关的不良事件。